Discontinuation of Spironolactone

Indications for Discontinuation

The American College of Cardiology recommends that spironolactone should not be stopped abruptly without medical supervision, and discontinuation should only occur for specific clinical indications including severe hyperkalemia (potassium >6.0 mEq/L), severe renal dysfunction (creatinine rising above 310 μmol/L), or intolerable side effects like gynecomastia 1
Severe hyperkalemia, defined as potassium >6.0 mEq/L, requires immediate discontinuation and specific treatment, as recommended by the European Society of Cardiology 1
Severe renal dysfunction, defined as creatinine rising to >310 μmol/L, mandates complete discontinuation, according to the National Kidney Foundation 1

The European Journal of Heart Failure suggests that no formal taper is required for spironolactone discontinuation, unlike beta-blockers which carry rebound risk 2
However, in heart failure patients, abrupt discontinuation is associated with a two to fourfold higher risk of subsequent cardiovascular events, and a preferred approach is to attempt dose reduction first (halve the dose) and reassess in 1-2 weeks before complete discontinuation, as recommended by the American Heart Association 1

If gynecomastia is the issue, a direct switch to eplerenone without washout using a 2:1 conversion ratio (50 mg eplerenone = 25 mg spironolactone) can be considered, if potassium ≤5.0 mEq/L and creatinine <2.5 mg/dL, as suggested by the Endocrine Society 3
Reducing concomitant RAAS inhibitors, such as ACE inhibitors or ARBs, can help mitigate the risk of hyperkalemia or renal dysfunction, according to the American College of Cardiology 1

If spironolactone must be permanently stopped in heart failure patients, alternative therapies including maximizing beta-blocker doses, ensuring adequate ACE inhibitor/ARB therapy, or considering hydralazine-nitrate combination should be optimized, as recommended by the Heart Failure Society of America 1

In patients who develop severe hyperkalemia (serum potassium > 6.0 mmol/L), spironolactone should be stopped immediately and appropriate hyperkalemia treatment initiated. 4
When severe renal impairment occurs (serum creatinine rises above 310 µmol/L ≈ 3.5 mg/dL), spironolactone must be discontinued without delay. 4

For individuals with heart failure, the preferred approach is to halve the current spironolactone dose (e.g., from 50 mg daily to 25 mg daily, or from 25 mg daily to 12.5 mg on alternate days), reassess clinical status after 1–2 weeks, and then consider complete cessation if tolerated. 4

If hyperkalemia or renal dysfunction is present, potassium supplements should be discontinued rather than stopping spironolactone outright. 4

Serum potassium and creatinine should be re‑checked within 1 week after spironolactone is stopped to confirm resolution of the adverse laboratory abnormality that prompted discontinuation. 4

In patients with cirrhosis, clinicians should watch for the return of ascites during the first 1–2 weeks after spironolactone discontinuation. 5